Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. - Wikidata - wikimedia - TriplyDB

Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration.

Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration.

http://www.wikidata.org/entity/Q38032311

about

New Diagnostic and Therapeutic Approaches for Preventing the Progression of Diabetic Retinopathy Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4.Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and Meta-analysis Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)Long-term, therapy-related visual outcome of 49 cases with retinal arterial macroaneurysm: a case series and literature review.Efficacy of Antibody Delivery to the Retina and Optic Nerve by Topical Administration Aflibercept in wet AMD: specific role and optimal use.Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.In vitro and ex vivo retina angiogenesis assays.Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis.Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia.Efficacy and vitreous levels of topical NSAIDs.Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?Changes in Clotting Time, Plasma Fibrinogen Levels, and Blood Viscosity After Administration of Ranibizumab for Treatment of Choroidal Neovascularization.Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion.A Single Drop in the Eye - Effects on the Whole Body?Blood coagulation parameters after intravitreal injection of aflibercept in patients with neovascular age-related macular degeneration.

P2860

Q26765468-6FD8BA5A-E94E-42AC-8D86-AA00004CEFB4 Q33407740-C0C9740C-5BA4-40B9-8EE9-84E6D3BD26BA Q33912485-B431E28A-BB86-4A88-9675-F81B1881592E Q34624487-370D7331-C5EE-4491-A9F9-52D820AD2E84 Q35016867-0A4AB628-804D-4E01-A51D-CEBFD32D12E5 Q35604892-908F020D-B861-4A73-A854-E65EB09964A7 Q36881990-0BAAC92A-3E1A-4875-8DB2-65ABEF5284CC Q37109788-D25C35D0-C501-451D-8B28-4CA90163975E Q38128390-87ACD933-D2BA-47E1-B814-8ED55ED12B2F Q38152261-5F20C97F-D287-41CE-A3AD-017DCE625BAF Q38184936-93290964-2B7C-485A-A2DB-D91CBAE6CC97 Q38210239-A848E01F-049C-4B68-B591-42E20167F9EE Q38256840-F93D797B-0F32-448C-96FE-4231D207B9DA Q38546915-FFC673E2-A174-4535-8633-3B234A847B52 Q40990867-9FF62C73-5558-4A78-9813-6820D6C7544F Q41704393-E95A293E-0944-4330-8E6B-D9298490C3F1 Q43129563-191F741C-19A4-4B71-BB4B-166F81C74179 Q47116024-04C041D3-51B8-49CB-91A0-4BBDBC2B9DBE Q50062366-7AC7D1A6-893D-4FC4-8C15-80F9DBE6F34E

P2860

Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration.

http://www.wikidata.org/entity/Q38032311

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Systemic thromboembolic advers ...... -related macular degeneration.

@en

type

label

Systemic thromboembolic advers ...... -related macular degeneration.

@en

prefLabel

Systemic thromboembolic advers ...... -related macular degeneration.

@en

P1433

Q38032311-7ADE281D-DD96-4BD4-95EA-C74D73CAE9C4

P1476

Q38032311-7370FD4C-127E-4CB6-B393-3E9A9D799B79

P2093

Q38032311-0300E930-90BB-4C43-867A-565E2061ED67

Q38032311-2043E3CD-C141-4659-AC55-714AC7701BA3

Q38032311-2638DEBC-5388-4B1E-863E-1144C1D5D3DC

Q38032311-92578BA8-C9CF-4658-81A2-3EEDA1B7804C

Q38032311-BD4949DB-3F92-4FE5-88A2-77B5DCF370F1

Q38032311-D866AAE9-07CB-4116-97A7-39032719BA98

Q38032311-F3F79BD3-6EB7-4608-BABA-F988E0616F7F

P2860

Q38032311-011D565A-F0E2-468E-B515-52ED46350CBB

Q38032311-057C5AEA-F340-4F56-808F-636241D8F30C

Q38032311-05DF31CA-F753-4531-8B76-DC5334669E8B

Q38032311-0751463A-B05C-4087-8F4C-FC94EAA976B9

Q38032311-07E1895D-29EE-47BA-BE20-256D913F6C74

Q38032311-09566AE7-8FBE-40FF-A18C-E25CDC449E04

Q38032311-0A2D6AF1-6AA0-43F0-96AE-DFAE9D36B749

Q38032311-172372D4-A048-4573-A9A5-69A21F4F49F0

Q38032311-1A643930-034B-4100-8DDE-990BC2AA7437

Q38032311-1BAB431C-546C-469E-97D0-5E73D50C4C94

P304

Q38032311-AAD297CD-D9EF-4B16-9592-3D478312635A

P31

Q38032311-656BF428-ADC0-4256-B50F-33E3D1F1E0B3

P356

Q38032311-9E1FD9C5-D5F2-4713-B4CA-B8D337B03397

P407

Q38032311-D18ECAEB-0C49-42B9-BD0C-63C18FD62E79

P433

Q38032311-76E6A86B-9F27-4CC0-B1D8-97F887BA89FD

P478

Q38032311-4650E75D-D8CE-479E-8771-781BBE92EBF8

P50

Q38032311-B06D67EE-276B-4BBC-82EB-AA13C0940E10

P577

Q38032311-B3D181C0-313D-4817-AC1E-36881AA137BB

P5875

Q38032311-EC091BFA-26EA-4EBE-910E-CE4E96A3DD7D

P698

Q38032311-5E561A07-8472-4158-9CD0-BFB7547239B7

P921

Q38032311-C2B42928-5959-4712-8646-EE7274881981

P356

14712598.2012.707176

P1433

Expert Opinion on Biological Therapy

P1476

Systemic thromboembolic advers ...... -related macular degeneration.

@en

P2093

Barbara Arcidiacono

http://www.w3.org/2001/XMLSchema#string

Francesco Semeraro

http://www.w3.org/2001/XMLSchema#string

Luca Agnifili

http://www.w3.org/2001/XMLSchema#string

Marco Verolino

http://www.w3.org/2001/XMLSchema#string

Rodolfo Mastropasqua

http://www.w3.org/2001/XMLSchema#string

Sarah Duse

http://www.w3.org/2001/XMLSchema#string

Vincenzo Fasanella

http://www.w3.org/2001/XMLSchema#string

P2860

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

VEGF inhibition and renal thrombotic microangiopathy

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo

Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function

P304

1299-1313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2012.707176

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Ciro Costagliola

P577

2012-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230621687

http://www.w3.org/2001/XMLSchema#string

P698

22866908

http://www.w3.org/2001/XMLSchema#string

P921

thromboembolism